Regulatory aspects of xenotransplantation in Korea

Background The xenotransplant clinical trial with human subjects seems to be technically feasible, however, it needs the strict regulatory framework from the domestic as well as the international level to make sure the safety of the human subject and the general public. Methods The authors reviewed...

Full description

Saved in:
Bibliographic Details
Published in:Xenotransplantation (Københaven) 2020-05, Vol.27 (3), p.e12602-n/a
Main Authors: Kwon, Ivo, Park, Chung‐Gyu, Lee, SeungHwan
Format: Article
Language:English
Subjects:
clinical trial
Clinical trials
Human subjects
Korean regulation
Regenerative medicine
Xenografts
xenotransplantation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The xenotransplant clinical trial with human subjects seems to be technically feasible, however, it needs the strict regulatory framework from the domestic as well as the international level to make sure the safety of the human subject and the general public. Methods The authors reviewed and introduced the current regulations regarding the xenotransplant clinical trial in Korea focusing on the recently stipulated act (Advanced Regenerative Medicine and Biopharmacology Act, ARMBA) and the role of the related government agencies and health institutions. Results and Conclusion Korea is ready to conduct the xenotransplant clinical trial with human subjects in the current regulatory framework satisfying the requirements of the international guidance. The responsible governmental agencies would collaborate in control the xenotransplant clinical trial under the ARMBA and other related acts and guidance.
ISSN:0908-665X
1399-3089
DOI:10.1111/xen.12602